BRL 48962

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: BRL 48962
• 英文别名: (R)-2-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-isoindole；Tocris-1133；(1R)-2-(4,5-dihydro-1H-imidazol-2-ylmethyl)-1-methyl-1,3-dihydroisoindole
• 化学式: C₁₃H₁₇N₃
• 分子量: 215.298
• InChiKey: SGOFAUSEYBZKDQ-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  27.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (R)-1,3-dihydro-1-methyl-2H-isoindole-2-acetonitrile 、 乙二胺 在 二硫化碳 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 BRL 48962
  参考文献：
  名称：

  EP413433

  摘要：

  公开号：

文献信息

• Isoindolyl-imidazole-derivatives and pharmaceutical compositions
  申请人：Beecham Group p.l.c.

  公开号：EP0413433A1

  公开（公告）日：1991-02-20

  A compound of formula (I): or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: R represents an alkyl group; Ro represents a hydrogen atom, an alkyl group, a benzyl group or an alkanoyl group; and X represents a hydrogen atom or a halogen atom; a process for preparing such a compound, a pharmaceutical composition for preparing such a compound and the use of such compounds and compositions in medicine.

  式(I)化合物： 或其药学上可接受的盐，或其药学上可接受的溶液，其中 R 代表烷基； Ro 代表氢原子、烷基、苄基或烷酰基；及 X 代表氢原子或卤素原子；制备此类化合物的工艺、制备此类化合物的药物组合物以及此类化合物和组合物的医药用途。
• TREATMENT
  申请人：MOOKERJEE Rajeshwar

  公开号：US20210085668A1

  公开（公告）日：2021-03-25

  The present invention derives from the unexpected finding that ADRA2a antagonists decrease fibrosis in non-alcoholic fatty liver disease (NAFLD). Thus, by antagonising ADRA2a, many of the unwanted consequences or symptoms of NAFLD, may be reduced, such as impaired cognitive activity and fibrosis progression. The present invention utilises these findings to identify and provide ADRA2a antagonists that may be used in the treatment of fibrosis in NAFLD.
• [EN] TREATMENT<br/>[FR] TRAITEMENT
  申请人：UCL BUSINESS PLC

  公开号：WO2019186160A1

  公开（公告）日：2019-10-03

  The present invention derives from the unexpected finding that ADRA2a antagonists decrease fibrosis in non-alcoholic fatty liver disease (NAFLD). Thus, by antagonising ADRA2a, many of the unwanted consequences or symptoms of NAFLD, may be reduced, such as impaired cognitive activity and fibrosis progression. The present invention utilises these findings to identify and provide ADRA2a antagonists that may be used in the treatment of fibrosis in NAFLD.